Trial Profile
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of IDN-6556 in Subjects With Non-Alcoholic Fatty Liver Disease and Raised Transaminases
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Emricasan (Primary)
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Acronyms NAFLD
- Sponsors Conatus Pharmaceuticals
- 14 Nov 2018 Results published in the Alimentary Pharmacology and Therapeutics
- 20 Apr 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 26 Mar 2015 According to Conatus Pharmaceuticals media release, detailed results from this trial will be presented in a late-breaker poster at The International Liver Congress 2015, the 50th Annual Meeting of the European Association for the Study of the Liver (EASL).